

Hans Erik Johnsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1558516/publications.pdf>

Version: 2024-02-01

45
papers

4,732
citations

516215

16
h-index

288905

40
g-index

45
all docs

45
docs citations

45
times ranked

6529
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission â€œ results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. <i>BMC Cancer</i> , 2022, 22, 147.	1.1	1
2	Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network. <i>Haematologica</i> , 2021, 106, 1496-1499.	1.7	9
3	Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2020, 38, 3252-3260.	0.8	102
4	High-Throughput Sequencing-Based Investigation of Viruses in Human Cancers by Multienrichment Approach. <i>Journal of Infectious Diseases</i> , 2019, 220, 1312-1324.	1.9	13
5	A B-cellâ€™associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology. <i>Blood Advances</i> , 2018, 2, 1542-1546.	2.5	13
6	Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial. <i>Blood</i> , 2018, 132, 3186-3186.	0.6	3
7	Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow â€™ A proof of concept study. <i>PLoS ONE</i> , 2018, 13, e0193249.	1.1	8
8	Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 778-784.	0.8	72
9	Molecular classification of tissue from a transformed non-Hogkinâ€™s lymphoma case with unexpected long-time remission. <i>Experimental Hematology and Oncology</i> , 2017, 6, 3.	2.0	2
10	Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival. <i>Leukemia and Lymphoma</i> , 2017, 58, 2695-2704.	0.6	11
11	Anthropometrics and prognosis in diffuse large Bâ€™cell lymphoma: a multicentre study of 653 patients. <i>European Journal of Haematology</i> , 2017, 98, 355-362.	1.1	2
12	A systematic review of molecular responses to cancer therapy in normal human mucosa. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017, 124, 355-366.	0.2	3
13	R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 1105-1113.	0.6	26
14	miR-155 as a Biomarker in B-Cell Malignancies. <i>BioMed Research International</i> , 2016, 2016, 1-14.	0.9	56
15	hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine. <i>PLoS ONE</i> , 2016, 11, e0163711.	1.1	7
16	The myeloma stem cell concept, revisited: from phenomenology to operational terms. <i>Haematologica</i> , 2016, 101, 1451-1459.	1.7	55
17	The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines. <i>Biomarker Research</i> , 2016, 4, 12.	2.8	29
18	Characterization of memory B cells from thymus and its impact for DLBCL classification. <i>Experimental Hematology</i> , 2016, 44, 982-990.e11.	0.2	3

#	ARTICLE	IF	CITATIONS
19	High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma. <i>Experimental Hematology</i> , 2016, 44, 238-246.e2.	0.2	46
20	Long Noncoding RNA Expression during Human B-Cell Development. <i>PLoS ONE</i> , 2015, 10, e0138236.	1.1	80
21	Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. <i>BMC Cancer</i> , 2015, 15, 235.	1.1	44
22	Inherited variation in immune response genes in follicular lymphoma and diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 3257-3266.	0.6	7
23	Outcome prediction by extranodal involvement, IPI, R _i -IPI, and NCCN _i -IPI in the PET/CT and rituximab era: A <sc>D</sc>-anish ⁴ <sc>C</sc>-anadian study of 443 patients with diffuse ⁴ <sc>B</sc>- ⁴ cell lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 1041-1046.	2.0	71
24	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. <i>Haematologica</i> , 2015, 100, 1254-1266.	1.7	289
25	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood ⁴ and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146
26	Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish ⁴ Swedish Population-Based Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3993-3998.	0.8	74
27	The Absolute Number of Extranodal Sites Detected By PET-CT Is a Powerful Predictor of Secondary Central Nervous System Involvement in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. <i>Blood</i> , 2015, 126, 3905-3905.	0.6	1
28	Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project. <i>Blood</i> , 2015, 126, 4146-4146.	0.6	2
29	Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis. <i>PLoS ONE</i> , 2015, 10, e0116966.	1.1	10
30	Inherited Inflammatory Response Genes Are Associated with B-Cell Non-Hodgkin ⁴ ™s Lymphoma Risk and Survival. <i>PLoS ONE</i> , 2015, 10, e0139329.	1.1	7
31	MicroRNAs in B-cells: from normal differentiation to treatment of malignancies. <i>Oncotarget</i> , 2015, 6, 7-25.	0.8	24
32	Subtyping of B-Cell Malignancies By B-Cell Subset Associated Gene Signatures (BAGS), Generated from Human Primary and Secondary Lymphoid Organs.. <i>Blood</i> , 2015, 126, 5347-5347.	0.6	0
33	The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. <i>Haematologica</i> , 2014, 99, 984-996.	1.7	124
34	Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma. <i>Experimental Hematology</i> , 2014, 42, 927-938.	0.2	15
35	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	5.1	3,343
36	Validation and implementation of a method for microarray gene expression profiling of minor B-cell subpopulations in man. <i>BMC Immunology</i> , 2014, 15, 3.	0.9	10

#	ARTICLE	IF	CITATIONS
37	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2014, 124, 35-35.	0.6	11
38	Prognostic Impact of Extranodal Diffuse Large B-Cell Lymphoma in the Era of Immunochemotherapy and PET/CT Staging. <i>Blood</i> , 2014, 124, 1630-1630.	0.6	1
39	Clinical Features and Outcome in Newly Diagnosed Hodgkin Lymphoma Patients Presenting with PET/CT-Ascertained Focal Skeletal Lesions.. <i>Blood</i> , 2012, 120, 2637-2637.	0.6	0
40	Combination of the IGF-1 Receptor Inhibitor Picropodophyllin and the BH3 Mimetic ABT-737 Has Synergistic Anti-Myeloma Activity. <i>Blood</i> , 2012, 120, 4010-4010.	0.6	0
41	Disease Extent in Newly Diagnosed Hodgkin Lymphoma: A Comparison of CT and PET/CT Staged Patients. <i>Blood</i> , 2012, 120, 1532-1532.	0.6	0
42	Gene Expression Profiling of Murine T-Cell Lymphoblastic Lymphoma Identifies Deregulation of S-Phase Initiating Genes.. <i>Blood</i> , 2012, 120, 2395-2395.	0.6	4
43	Randomized Controlled Trial of Two Different Dosing Regimens of Palifermin to Prevent Mucositis In Multiple Myeloma Patients Receiving One-Day Administration of High-Dose Melphalan. <i>Blood</i> , 2010, 116, 904-904.	0.6	5
44	Febrile Neutropenia Risk Assessment and Granulocyte-Colony Stimulating Factor Support in Patients with Diffuse Large B Cell Lymphoma Receiving R-CHOP Regimens.. <i>Blood</i> , 2009, 114, 107-107.	0.6	3
45	Impact of Growth Factor Independence 1 in Human T-Cell Lymphomas; Pathogenic Potential Identified by Insertional Mutagenesis in a Murine T-Cell Lymphoma Model.. <i>Blood</i> , 2009, 114, 5047-5047.	0.6	0